hVIVO (LON:HVO) Stock Price Down 3.3% - Here's Why

Key Points

• hVIVO's stock price fell by 3.3% on Wednesday, trading as low as GBX 8.30 before closing at GBX 8.70, with a significant increase in trading volume of 164% compared to its average.
• Research analysts maintain a generally positive outlook, with Peel Hunt setting a price target of GBX 21 and Shore Capital issuing a price target of GBX 35, leading to an average target price of GBX 28.
• hVIVO reported a net margin of 25.96% and a return on equity of 47.93%, with forecasts for the current year projecting earnings per share of approximately 1.55.

hVIVO plc (LON:HVO - Get Free Report)'s share price was down 3.3% on Wednesday . The stock traded as low as GBX 8.30 ($0.11) and last traded at GBX 8.70 ($0.12). Approximately 7,687,127 shares changed hands during trading, an increase of 164% from the average daily volume of 2,914,998 shares. The stock had previously closed at GBX 9 ($0.12).

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on HVO shares. Peel Hunt reissued an "add" rating and set a GBX 21 price objective on shares of hVIVO in a research note on Tuesday, July 29th. Shore Capital reaffirmed a "buy" rating and issued a GBX 35 price target on shares of hVIVO in a research note on Tuesday, July 22nd. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat, hVIVO currently has an average rating of "Buy" and an average target price of GBX 28.

hVIVO Stock Performance

The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock's 50 day simple moving average is GBX 9.98 and its two-hundred day simple moving average is GBX 12.79. The stock has a market cap of £58.00 million, a P/E ratio of 544.52 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last announced its quarterly earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, research analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.